AbCellera (NASDAQ:ABCL) today announced that executives from the Company will present at the following investor conferences: Piper Sandler 36th Annual Healthcare Conference in New York, NY on Tuesday, December 3, 2024, at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time) 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025, at 4:30 p.m. Pacific Time (7:30 p.m. Eastern Time) Live audio webcasts of the presentation may be accessed through the link that will be posted on AbCellera's Investor Relations website. Replays of the webcast will be available through the same links following the presentations. About AbCellera Biologics Inc. AbCel

AbCellera (NASDAQ:ABCL) today announced new data on its T-cell engager (TCE) platform, to be presented as a poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting at the George R. Brown Convention Center in Houston, Texas. AbCellera's presentation, which is available for viewing here, describes: Strategies to address key challenges in TCE development: CD3-binding antibodies to widen the therapeutic window by generating TCEs with potent tumor-cell killing and optimal cytokine release Molecules to enhance efficacy for solid tumor indications by increasing T-cell activation and proliferation through costimulation of CD28 and 4-1BB Application of the platform to tw

AbCellera (NASDAQ:ABCL) today announced financial results for the third quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "Through the third quarter we continued to execute on our key priorities of advancing our internal pipeline and building capabilities to support clinical trials activities in 2025 and beyond," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "Notably, we completed the consolidation into our new headquarters in Vancouver, Canada, which marks a significant milestone towards completing our platform and infrastructure investments." Q3 2024 Business Summary Expanded existing collaboration with E

AbCellera (NASDAQ:ABCL) today announced that executives from the Company will be presenting at the following investor conferences: Stifel Healthcare Conference on Monday, November 18, 2024, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:00 a.m. Pacific Time (5:00 p.m. Greenwich Mean Time) Live audio webcasts of each presentation may be accessed through links that will be posted on AbCellera's Investor Relations website. Replays of each webcast will be available through the same links following the presentations. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medic

AbCellera (NASDAQ:ABCL) today announced an upcoming poster presentation on its T-cell engager platform at the SITC 39th Annual Meeting, to be held November 6 to 10 at the George R. Brown Convention Center in Houston, Texas. Details on AbCellera's poster presentation at SITC are as follows: Title: Profiling bispecific T-cell engagers: Strategies for enhancing potency while minimizing cytokine release Abstract Number: 1291 Date and Time: Friday, November 8 from 9:00 a.m. to 7:00 p.m. CST Location: Exhibit Halls A B George R. Brown Convention Center or online at https://www.sitcancer.org/2024/home About AbCellera's T-Cell Engager Platform CD3 T-cell engagers have the potential to be a corn

AbCellera (NASDAQ:ABCL) will announce its third quarter 2024 financial results on Monday, November 4, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, data

AbCellera (NASDAQ:ABCL) today announced that executives from the Company will be presenting at the following investor conferences: Wells Fargo Healthcare Conference on Thursday, September 5, 2024, at 12:00 p.m. Pacific Time (3:00 p.m. Eastern Time) Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) Live audio webcasts of each presentation may be accessed through links that will be posted on AbCellera's Investor Relations website. Replays of each webcast will be available through the same links following the presentations. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody me

AbCellera (NASDAQ:ABCL) today announced financial results for the second quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "This quarter, we made important progress on our internal pipeline and aim to submit applications for clinical trials for ABCL635 and ABCL575 in the second quarter of 2025. In parallel, we have focused preclinical work on our T-cell engager platform to four molecules for indications in oncology and autoimmunity," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "Since our last earnings release, two of our partners have achieved notable milestones, including Abdera's IND clearance and Fast Tr

AbCellera (NASDAQ:ABCL) announced today that it has expanded its existing collaboration with Eli Lilly and Company (Lilly) to discover therapeutic antibodies for programs in immunology, cardiovascular disease, and neuroscience. The expansion builds upon the successful research collaboration established in March 2020, which included eight de novo programs for targets selected by Lilly and an exclusive license to AbCellera's COVID-19 antibody program. AbCellera has advanced all eight programs under the original agreement, and the licensed program resulted in emergency use authorization by the U.S. Food and Drug Administration for two COVID-19 antibody therapies co-developed by the companies

AbCellera (NASDAQ:ABCL) will announce its second quarter 2024 financial results on Tuesday, August 6, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, d

10-Q - AbCellera Biologics Inc. (0001703057) (Filer)

8-K - AbCellera Biologics Inc. (0001703057) (Filer)

SCHEDULE 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)

10-Q - AbCellera Biologics Inc. (0001703057) (Filer)

8-K - AbCellera Biologics Inc. (0001703057) (Filer)

8-K - AbCellera Biologics Inc. (0001703057) (Filer)

10-Q - AbCellera Biologics Inc. (0001703057) (Filer)

8-K - AbCellera Biologics Inc. (0001703057) (Filer)

ARS - AbCellera Biologics Inc. (0001703057) (Filer)

DEFA14A - AbCellera Biologics Inc. (0001703057) (Filer)

SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)

SC 13G - AbCellera Biologics Inc. (0001703057) (Subject)

SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)

SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)

SC 13D/A - AbCellera Biologics Inc. (0001703057) (Subject)

SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)

SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)

SC 13G - AbCellera Biologics Inc. (0001703057) (Subject)

SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)

SC 13G - AbCellera Biologics Inc. (0001703057) (Subject)

The Benchmark Company downgraded AbCellera Biologics from Buy to Hold

The Benchmark Company upgraded AbCellera Biologics from Hold to Buy and set a new price target of $9.00

KeyBanc Capital Markets initiated coverage of AbCellera Biologics with a rating of Overweight and set a new price target of $6.00

The Benchmark Company downgraded AbCellera Biologics from Buy to Hold

Piper Sandler resumed coverage of AbCellera Biologics with a rating of Overweight and set a new price target of $20.00

Cowen initiated coverage of AbCellera Biologics with a rating of Outperform

Goldman initiated coverage of AbCellera Biologics with a rating of Buy and set a new price target of $30.00

Truist initiated coverage of AbCellera Biologics with a rating of Buy and set a new price target of $29.00

Credit Suisse reiterated coverage of AbCellera Biologics with a rating of Outperform and set a new price target of $40.00 from $39.00 previously

SVB Leerink reiterated coverage of AbCellera Biologics with a rating of Outperform and set a new price target of $20.00 from $25.00 previously

4 - AbCellera Biologics Inc. (0001703057) (Issuer)

4 - AbCellera Biologics Inc. (0001703057) (Issuer)

4 - AbCellera Biologics Inc. (0001703057) (Issuer)

4 - AbCellera Biologics Inc. (0001703057) (Issuer)

4 - AbCellera Biologics Inc. (0001703057) (Issuer)

4 - AbCellera Biologics Inc. (0001703057) (Issuer)

4 - AbCellera Biologics Inc. (0001703057) (Issuer)

4 - AbCellera Biologics Inc. (0001703057) (Issuer)

4 - AbCellera Biologics Inc. (0001703057) (Issuer)

4 - AbCellera Biologics Inc. (0001703057) (Issuer)

4 - AbCellera Biologics Inc. (0001703057) (Issuer)

4 - AbCellera Biologics Inc. (0001703057) (Issuer)

4 - AbCellera Biologics Inc. (0001703057) (Issuer)

Keybanc analyst Scott Schoenhaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and lowers the price target from $7 to $5.

Keybanc analyst Scott Schoenhaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and lowers the price target from $8 to $7.

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. The company reported quarterly sales of $9.954 million which missed the analyst consensus estimate of $10.836 million by 8.14 percent. This is a 18.36 percent decrease over sales of $12.192 million the same period last year.

Data show how AbCellera is expanding the reach of T-cell engagers with:CD3-binding antibodies that consistently generate T-cell engagers with potent tumor-cell killing and low cytokine release across multiple tumor targets, including PSMA, B7-H4, and 5T4Costimulatory CD28-binding antibodies that stimulate T cells without superagonist activityHighly specific T-cell engagers for the peptide-MHC target MAGE-A4AbCellera (NASDAQ:ABCL) today announced new data on its T-cell engager (TCE) programs at the American Association for Cancer ResearchⓇ (AACR) Annual Meeting 2024 at the San Diego Convention Center, with three posters being presented on April 8 and one on April 9. Together, AbCellera's data

AbCellera (NASDAQ:ABCL) and Biogen Inc. (NASDAQ:BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience."Delivering biologics across the blood brain barrier is one of the most important and long-standing problems in neuroscience," said Murray McCutcheon, Ph.D., SVP, Partnering at AbCellera. "We are excited to work with Biogen on this innovative program, which has the potential to unlock multiple new approaches to treating neurological conditions."Under the terms of the agreement, AbCellera will receive an upfront payment and is eligible to receive additional milestone

Benchmark analyst Robert Wasserman upgrades AbCellera Biologics (NASDAQ:ABCL) from Hold to Buy.

AbCellera Biologics (NASDAQ:ABCL) reported its Q4 earnings results on Tuesday, February 20, 2024 at 04:05 PM. Here's what investors need to know about the announcement. Earnings AbCellera Biologics missed estimated earnings by 30.77%, reporting an EPS of $-0.17 versus an estimate of $-0.13. Revenue was down $12.37 million from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.03 which was followed by a 6.09% increase in the share price the next day. Here's a look at AbCellera Biologics's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -0.13 -0.13 -0.14 0 EPS Actual -0.10 -0.11 -0.14 -0.1 Revenue Estimate 11.90M 1

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 30.77 percent. The company reported quarterly sales of $9.18 million which beat the analyst consensus estimate of $8.88 million by 3.31 percent. This is a 57.40 percent decrease over sales of $21.55 million the same period last year.

Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. • Fresenius Medical Care (NYSE:FMS) is projected to report quarterly earnings at $0.32 per share on revenue of $5.35 billion. • NexPoint Residential (NYSE:NXRT) is projected to report earnings for its fourth quarter. • Summit Therapeutics (NASDAQ:SMMT) is likely to report earnings for its fourth quarter. • Axsome Therapeutics (NASDAQ:AXSM) is projected to report quarterly loss at $1.15 per share on revenue of $67.69 million. • Gran Tierra Energy (AMEX:GTE) is expected to report quarterly loss at $0.13 per share on revenue of $60 thousand. • O

AbCellera (NASDAQ:ABCL) today announced financial results for the third quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "Through the third quarter we continued to execute on our key priorities of advancing our internal pipeline and building capabilities to support clinical trials activities in 2025 and beyond," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "Notably, we completed the consolidation into our new headquarters in Vancouver, Canada, which marks a significant milestone towards completing our platform and infrastructure investments." Q3 2024 Business Summary Expanded existing collaboration with E

AbCellera (NASDAQ:ABCL) will announce its third quarter 2024 financial results on Monday, November 4, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, data

AbCellera (NASDAQ:ABCL) today announced financial results for the second quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "This quarter, we made important progress on our internal pipeline and aim to submit applications for clinical trials for ABCL635 and ABCL575 in the second quarter of 2025. In parallel, we have focused preclinical work on our T-cell engager platform to four molecules for indications in oncology and autoimmunity," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "Since our last earnings release, two of our partners have achieved notable milestones, including Abdera's IND clearance and Fast Tr

AbCellera (NASDAQ:ABCL) will announce its second quarter 2024 financial results on Tuesday, August 6, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, d

AbCellera (NASDAQ:ABCL) today announced financial results for the first quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "We continue to execute on advancing our internal pipeline, completing capital investments in forward integration, and expanding strategic partnerships," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "This quarter, presentations on our T-cell engager platform, which includes our highly differentiated CD3 panel, demonstrated how we can repeatedly generate TCEs that maximize tumor-cell killing without inducing excessive cytokine release. With our TCE platform in place, we are moving programs

AbCellera (NASDAQ:ABCL) will announce its first quarter 2024 financial results on Tuesday, May 7, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, data

Total revenue of $38 million, compared to $485 million in FY 2022 Total cumulative partner-initiated program starts with downstreams of 87, with 12 new starts in the year Net loss of $0.51 per share on a basic and diluted basis, compared to earnings of $0.56 (basic) and $0.50 (diluted) per share in 2022 AbCellera (NASDAQ:ABCL) today announced financial results for the full year 2023. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "In 2023 we began shifting capital allocation from building capabilities to using them, which includes advancement of our first internal programs and strategic partnerships," said Carl Hansen, Ph

AbCellera (NASDAQ:ABCL) will announce its full year 2023 financial results on Tuesday, February 20, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera is breaking the barriers of conventional antibody discovery to bring better medicines to patients, sooner. AbCellera's engine integrates expert teams, technology, and facilities with the data science and automation needed

Total revenue of $7 million, compared to $101 million in Q3 2022 Total cumulative partnered program starts of 110, up 20% from Q3 2022 Net loss of $0.10 per share on a basic and diluted basis, compared to net earnings of $0.09 and $0.08 per share on a basic and diluted basis, respectively, in Q3 2022 AbCellera (NASDAQ:ABCL) today announced financial results for the third quarter of 2023. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "In the third quarter we achieved a company milestone with AbCellera advancing two AbCellera-led programs into IND-enabling studies," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "T

AbCellera (NASDAQ:ABCL) will announce its third quarter 2023 financial results on Thursday, November 2, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera is breaking the barriers of conventional antibody discovery to bring better medicines to patients, sooner. AbCellera's engine integrates expert teams, technology, and facilities with the data science and automation neede

AbCellera (NASDAQ:ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective March 7, 2024. "AbCellera continues to expand the frontier of biotech, a nefariously difficult and vital field," said Peter Thiel. "I am proud to have helped them with their mission." Mr. Thiel joined AbCellera's Board of Directors in November 2020 and served as the Chairman of the Company's Nominating and Corporate Governance Committee. Effective March 7, 2024, Dr. Andrew Lo, a member of the Company's Board of Directors, will be appointed to the Nominating and Corporate Governance Committee of the Board of Dir

TORONTO, June 13, 2023 /PRNewswire/ -- DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with brain disorders and aging, today announced the appointment of John Reilly as the company's Chief Executive Officer and member of the Board of Directors. Mr. Reilly brings two decades of leadership experience building and creating value for biotechnology companies, with deep knowledge and expertise in corporate strategy, business dev

AbCellera (NASDAQ:ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced changes to its Board of Directors with the appointment of Andrew W. Lo, Ph.D., as an independent director and the resignation of John Hamer, Ph.D. Changes are effective immediately. Dr. Lo has developed new financial engineering tools and business models for drug and device development and healthcare delivery, statistical methods for incorporating patient preferences into the drug approval process, and machine-learning for predicting clinical trial outcomes. He will serve on the Audit and Compensation Committees of the Board of Directors. "Andrew is a d

AbCellera (NASDAQ:ABCL), a technology company with a centralized operating system for next-generation antibody discovery, announced today the appointment of Neil Aubuchon as Chief Commercial Officer (CCO). Mr. Aubuchon brings over 20 years of experience in strategic planning, operations, and leadership for global biopharmaceutical companies, including tenures at Amgen and Eli Lilly and Company (Lilly). As Chief Commercial Officer, Mr. Aubuchon will lead the commercial strategy and assessment of partnership opportunities to optimize the value of AbCellera's growing portfolio of royalty positions in the next generation of antibody-based therapies. "AbCellera is selective in partnering and ev

AbCellera (NASDAQ:ABCL), a technology company with a centralized operating system for next-generation antibody discovery, announced today that Neil Berkley has been appointed as Chief Business Officer (CBO). Mr. Berkley's role will include leading the strategy and continued growth of AbCellera's partnership business, which currently includes a diverse portfolio of more than 100 programs with drug developers of all sizes. "Neil brings a wealth of business development experience that will be instrumental as we continue to execute our long-term strategy of using partnerships to accelerate the development of antibody therapeutics for a wide array of diseases," said Carl Hansen, Ph.D., CEO of A

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (NASDAQ: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the full year 2020 with the following highlights. “AbCellera had a breakthrough year, demonstrating strong growth across every area of the business and the effectiveness of our technology and business model through our discovery of the first monoclonal antibody therapy for COVID-19,” said Carl Hansen, Ph.D., President and CEO of AbCellera. “Each program improves our platform, and we continue to invest in new technologies that enhance and expand our capabilities to discover hig

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) announced today that Ester Falconer, Ph.D., has been appointed as Chief Technology Officer (CTO), effective January 28, 2021. As CTO, Dr. Falconer will lead AbCellera’s long-term strategy in the development, aggregation, and integration of technologies that improve the speed and success of therapeutic antibody discovery from target to investigational new drug application submission. “Dr. Falconer is an accomplished and creative technologist whose contributions have been indispensable to AbCellera’s success. She is also one of our strongest leaders and an effective mentor with a proven ability to build high-pe

NEW YORK--(BUSINESS WIRE)--Catalio Capital Management, LP (Catalio), a multi-strategy life sciences investment firm, has today announced the launch of their Credit Opportunities strategy to expand the scope of the firm’s investments across the biomedical technology industry and meet the growing demand for non-dilutive growth capital within the sector. The Catalio Credit Opportunities strategy seeks to provide senior-secured structured credit to breakthrough biomedical companies, targeting well-capitalized, pre-cashflow businesses with significant support from institutional investors. The strategy will be led by Co-Portfolio Managers John Henry Iucker and Robert Snyder. Mr. Iucker